Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 6/2021

15.11.2021 | Central Nervous System and Cognition (S Spudich, Section Editor)

Soluble Biomarkers of Cognition and Depression in Adults with HIV Infection in the Combination Therapy Era

verfasst von: Albert M. Anderson, Qing Ma, Scott L. Letendre, Jennifer Iudicello

Erschienen in: Current HIV/AIDS Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cognitive impairment and depression continue to be common among people with HIV (PWH) in the combination antiretroviral therapy (ART) era. A better understanding of the biological mechanisms that may underpin these disorders is needed. The purpose of this review is to describe published findings on soluble biomarkers from blood and cerebrospinal fluid (CSF) that have been associated with either cognition or depression among PWH in the setting of ART.

Recent Findings

Several biomarkers, including those that reflect viral persistence, monocyte/macrophage activation, and other processes, are associated with cognition and depressive symptoms. Some but not all results have been consistent across multiple studies. More research has been published on biomarkers of cognition relative to biomarkers of depression (particularly from CSF).

Summary

More studies are needed that investigate multiple biomarkers to understand the role of distinct but additive pathways in these disorders and to guide the development of new therapies. 
Literatur
1.
Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–96.PubMedPubMedCentralCrossRef
2.
Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016;86:334–40.PubMedPubMedCentralCrossRef
3.
Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis. Neurology. 2020;95:e2610–21.PubMedCrossRef
4.
Wei J, Hou J, Su B, et al. The prevalence of Frascati-criteria-based HIV-associated neurocognitive disorder (HAND) in HIV-infected adults: a systematic review and meta-analysis. Front Neurol. 2020;11:581346.PubMedPubMedCentralCrossRef
5.
Ettenhofer ML, Foley J, Castellon SA, Hinkin CH. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology. 2010;74:1217–22.PubMedPubMedCentralCrossRef
6.
7.
Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355:2283–96.
8.
Tozzi V, Balestra P, Galgani S, et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses. 2003;19:643–52.PubMedCrossRef
9.
Saylor D, Nakigozi G, Nakasujja N, et al. HIV associated neurocognitive disorder leads to death. Abstract 425. 2019 Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, March 4–7; 2019.
10.
Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21:706–13.PubMedCrossRef
11.
Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.PubMedCrossRef
12.
Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725–30.PubMedCrossRef
13.
Cook JA, Burke-Miller JK, Steigman PJ, et al. Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. AIDS Behav. 2018;22:3141–54.PubMedPubMedCentralCrossRef
14.
15.
Do AN, Rosenberg ES, Sullivan PS, et al. Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. PloS one. 2014;9:e92842.PubMedPubMedCentralCrossRef
16.
Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:384–90.PubMedCrossRef
17.
Kacanek D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr. 2010;53:266–72.PubMedPubMedCentralCrossRef
18.
Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA, J Am Med Assoc. 2001;285:1466–74.CrossRef
19.
Paul R, Apornpong T, Prasitsuebsai W, et al. Cognition, emotional health, and immunological markers in children with long-term nonprogressive HIV. J Acquir Immune Defic Syndr. 2018;77:417–26.PubMedPubMedCentralCrossRef
20.
21.
Shiramizu B, Gartner S, Williams A, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS. 2005;19:45–52.PubMedCrossRef
22.
Shiramizu B, Williams AE, Shikuma C, Valcour V. Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci. 2009;21:68–74.PubMedPubMedCentralCrossRef
23.
Valcour VG, Shiramizu BT, Sithinamsuwan P, et al. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology. 2009;72:992–8.PubMedPubMedCentralCrossRef
24.•
Spudich S, Robertson KR, Bosch RJ, et al. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. J Clin Invest. 2019;129:3339–46.
25.
Cysique LA, Hey-Cunningham WJ, Dermody N, Chan P, Brew BJ, Koelsch KK. Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition. PloS one. 2015;10:e0120488.PubMedPubMedCentralCrossRef
26.
Besson GJ, Lalama CM, Bosch RJ, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014;59:1312–21.PubMedPubMedCentralCrossRef
27.
Ruhanya V, Jacobs GB, Nyandoro G, et al. Peripheral blood lymphocyte proviral DNA predicts neurocognitive impairment in clade C HIV. J Neurovirol. 2020;26:920–8.PubMedPubMedCentralCrossRef
28.
Anderson AM, Munoz-Moreno JA, McClernon DR, et al. Prevalence and correlates of persistent HIV-1 RNA in cerebrospinal fluid during antiretroviral therapy. J Infect Dis. 2017;215:105–13.PubMedCrossRef
29.
Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126:929–38.PubMedCrossRef
30.
Henderson LJ, Johnson TP, Smith BR, et al. Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy. AIDS. 2019;33(Suppl 2):S145–57.PubMedCrossRef
31.
Anderson AM, Tyor WR, Mulligan MJ, Waldrop-Valverde D, Lennox JL, Letendre SL. HIV p24 antigen is quantifiable at low concentrations in human cerebrospinal fluid with digital ELISA and is associated with decreased neuropsychological performance. Clin Infect Dis. 2018.
32.
Letendre S, Bharti A, Perez-Valero I, et al. Higher anti-cytomegalovirus immunoglobulin G concentrations are associated with worse neurocognitive performance during suppressive antiretroviral therapy. Clin Infect Dis. 2018;67:770–7.PubMedPubMedCentralCrossRef
33.
Bharti AR, McCutchan A, Deutsch R, et al. Latent Toxoplasma infection and higher Toxoplasma gondii immunoglobulin G levels are associated with worse neurocognitive functioning in HIV-infected adults. Clin Infect Dis. 2016;63:1655–60.PubMedPubMedCentralCrossRef
34.
Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet. 1997;349:692–5.PubMedCrossRef
35.
Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol. 1994;98:369–74.PubMedPubMedCentralCrossRef
36.
Cauwels A, Frei K, Sansano S, et al. The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol. 1999;162:4762–72.PubMedCrossRef
37.
Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr. 2011;57:371–9.PubMedPubMedCentralCrossRef
38.
Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr. 2012;60:234–43.PubMedPubMedCentralCrossRef
39.
Imp BM, Rubin LH, Tien PC, et al. Monocyte activation is associated with worse cognitive performance in HIV-infected women with virologic suppression. J Infect Dis. 2017;215:114–21.PubMedCrossRef
40.
Manner IW, Baekken M, Kvale D, et al. Markers of microbial translocation predict hypertension in HIV-infected individuals. HIV Med. 2013;14:354–61.PubMedCrossRef
41.
Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.PubMedPubMedCentralCrossRef
42.
Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:168–73.PubMedPubMedCentralCrossRef
43.
Eden A, Marcotte TD, Heaton RK, et al. Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PloS one. 2016;11:e0157160.PubMedPubMedCentralCrossRef
44.
Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27:1387–95.PubMedCrossRef
45.
Krebs SJ, Slike BM, Sithinamsuwan P, et al. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals. AIDS. 2016;30:1533–42.PubMedCrossRef
46.
Kuehne LK, Reiber H, Bechter K, Hagberg L, Fuchs D. Cerebrospinal fluid neopterin is brain-derived and not associated with blood-CSF barrier dysfunction in non-inflammatory affective and schizophrenic spectrum disorders. J Psychiatr Res. 2013;47:1417–22.PubMedCrossRef
47.
Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29:463–71.PubMedCrossRef
48.
Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988;23:339–46.PubMedCrossRef
49.
Burlacu R, Umlauf A, Marcotte TD, et al. Plasma CXCL10 correlates with HAND in HIV-infected women. J Neurovirol. 2020;26:23–31.PubMedCrossRef
50.
Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084–90.PubMedCrossRef
51.
Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002;59:371–8.PubMedCrossRef
52.
Sas AR, Bimonte-Nelson H, Smothers CT, Woodward J, Tyor WR. Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci. 2009;29:3948–55.PubMedPubMedCentralCrossRef
53.
Fritz-French C, Tyor W. Interferon-alpha (IFNalpha) neurotoxicity. Cytokine Growth Factor Rev. 2012;23:7–14.PubMedCrossRef
54.
Anderson AM, Fennema-Notestine C, Umlauf A, et al. CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol. 2015;21:559–67.PubMedPubMedCentralCrossRef
55.
Rho MB, Wesselingh S, Glass JD, et al. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun. 1995;9:366–77.PubMedCrossRef
56.
Lehmann C, Taubert D, Jung N, et al. Preferential upregulation of interferon-alpha subtype 2 expression in HIV-1 patients. AIDS Res Hum Retroviruses. 2009;25:577–81.PubMedCrossRef
57.
Cassol E, Misra V, Morgello S, Gabuzda D. Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J Neuroimmune Pharmacol. 2013;8:1087–97.PubMedPubMedCentralCrossRef
58.
Rubin LH, Benning L, Keating SM, et al. Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study. J Neurovirol. 2018;24:41–51.PubMedCrossRef
59.
Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA. 2002;99:13795–800.PubMedPubMedCentralCrossRef
60.
Agsalda-Garcia MA, Sithinamsuwan P, Valcour VG, et al. Brief Report: CD14+ enriched peripheral cells secrete cytokines unique to HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2017;74:454–8.PubMedPubMedCentralCrossRef
61.
Majumder S, Zhou LZ, Ransohoff RM. Transcriptional regulation of chemokine gene expression in astrocytes. J Neurosci Res. 1996;45:758–69.PubMedCrossRef
62.
Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83:3719–33.PubMedPubMedCentralCrossRef
63.
Fabbiani M, Muscatello A, Perseghin P, et al. Brief Report: Peripheral monocyte/macrophage phenotypes associated with the evolution of cognitive performance in HIV-infected patients. J Acquir Immune Defic Syndr. 2017;76:219–24.PubMedCrossRef
64.
Robertson K, Landay A, Miyahara S, et al. Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment. J Neurovirol. 2020;26:107–13.PubMedCrossRef
65.
Grauer OM, Reichelt D, Gruneberg U, et al. Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. Ann Clin Transl Neurol. 2015;2:906–19.PubMedPubMedCentralCrossRef
66.
Schrier RD, Hong S, Crescini M, et al. Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND). PloS one. 2015;10:e0116526.PubMedPubMedCentralCrossRef
67.
Van Geel WJ, Rosengren LE, Verbeek MM. An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods. 2005;296:179–85.PubMedCrossRef
68.
Yilmaz A, Blennow K, Hagberg L, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017;17:761–70.PubMedCrossRef
69.
Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration. J Neurol. 2007;254:1026–32.PubMedCrossRef
70.•
Guha D, Mukerji SS, Chettimada S, et al. CSF extracellular vesicles and neurofilament light protein as biomarkers of CNS injury in HIV-infected patients on antiretroviral therapy. AIDS. 2018.
71.
Gisslen M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–40.PubMedCrossRef
72.
Anderson AM, Easley KA, Kasher N, et al. Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. J Neurovirol. 2018;24:695–701.PubMedPubMedCentralCrossRef
73.
Pulliam L, Sun B, Mustapic M, Chawla S, Kapogiannis D. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer’s disease. J Neurovirol. 2019;25:702–9.PubMedPubMedCentralCrossRef
74.
Sun B, Fernandes N, Pulliam L. Profile of neuronal exosomes in HIV cognitive impairment exposes sex differences. AIDS. 2019;33:1683–92.PubMedCrossRef
75.
76.
Shiomura Y, Hirokawa N. Colocalization of microtubule-associated protein 1A and microtubule-associated protein 2 on neuronal microtubules in situ revealed with double-label immunoelectron microscopy. J Cell Biol. 1987;104:1575–8.PubMedCrossRef
77.
Shiomura Y, Hirokawa N. The molecular structure of microtubule-associated protein 1A (MAP1A) in vivo and in vitro. An immunoelectron microscopy and quick-freeze, deep-etch study. J Neurosci. 1987;7:1461–9.PubMedPubMedCentralCrossRef
78.
Avdoshina V, Mahoney M, Gilmore SF, et al. HIV influences microtubule associated protein-2: potential marker of HIV-associated neurocognitive disorders. AIDS. 2020;34:979–88.PubMedCrossRef
79.
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.PubMedCrossRef
80.
Hoenigl M, de Oliveira MF, Perez-Santiago J, et al. (1–>3)-beta-D-glucan levels correlate with neurocognitive functioning in HIV-infected persons on suppressive antiretroviral therapy: a cohort study. Medicine. 2016;95:e3162.PubMedPubMedCentralCrossRef
81.
Munoz-Nevarez LA, Imp BM, Eller MA, et al. Monocyte activation, HIV, and cognitive performance in East Africa. J Neurovirol. 2020;26:52–9.PubMedCrossRef
82.
Campbell JD, Moore D, Degerman R, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/muL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54:1204–11.PubMedCrossRef
83.
Liang T, Ma C, Wang T, et al. Galectin-9 promotes neuronal restoration via binding TLR-4 in a rat intracerebral hemorrhage model. Neuromolecular Med. 2020.
84.
Premeaux TA, D’Antoni ML, Abdel-Mohsen M, et al. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019;25:150–61.PubMedCrossRef
85.
Bandaru VV, Mielke MM, Sacktor N, et al. A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013;81:1492–9.PubMedPubMedCentralCrossRef
86.
Bora A, Ubaida Mohien C, Chaerkady R, et al. Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry. J Neurovirol. 2014;20:457–65.PubMedPubMedCentralCrossRef
87.
Cassol E, Misra V, Dutta A, Morgello S, Gabuzda D. Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS. 2014.
88.
Cysique LA, Brew BJ. Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm. J Neurovirol. 2019;25:710–21.PubMedCrossRef
89.
Kallianpur AR, Gittleman H, Letendre S, et al. Cerebrospinal fluid ceruloplasmin, haptoglobin, and vascular endothelial growth factor are associated with neurocognitive impairment in adults with HIV infection. Mol Neurobiol. 2019;56:3808–18.PubMedCrossRef
90.
Montoya JL, Iudicello J, Fazeli PL, et al. Elevated markers of vascular remodeling and arterial stiffness are associated with neurocognitive function in older HIV+ adults on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2017;74:134–41.PubMedPubMedCentralCrossRef
91.
Cantres-Rosario Y, Plaud-Valentin M, Gerena Y, Skolasky RL, Wojna V, Melendez LM. Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders. AIDS. 2013;27:347–56.PubMedCrossRef
92.
Hileman CO, Azzam S, Schlatzer D, et al. Plasma citrate and succinate are associated with neurocognitive impairment in older people with HIV. Clin Infect Dis. 2021.
93.
Kalayjian RC, Robertson KR, Albert JM, et al. Plasma cystatin C associates with HIV-associated neurocognitive disorder but is a poor diagnostic marker in antiretroviral therapy-treated individuals. J Acquir Immune Defic Syndr. 2019;81:e49–54.PubMedPubMedCentralCrossRef
94.
Marcotte TD, Deutsch R, Michael BD, et al. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacol. 2013.
95.
Rubin LH, Xu Y, Norris PJ, et al. Early inflammatory signatures predict subsequent cognition in long-term virally suppressed women with HIV. Front Integr Neurosci. 2020;14:20.PubMedPubMedCentralCrossRef
96.
Hammond ER, Crum RM, Treisman GJ, et al. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol. 2016;22:479–87.PubMedPubMedCentralCrossRef
97.
Zuniga JA, Harrison ML, Henneghan A, Garcia AA, Kesler S. Biomarkers panels can predict fatigue, depression and pain in persons living with HIV: a pilot study. Appl Nurs Res. 2020;52:151224.PubMedCrossRef
98.
Rivera-Rivera Y, Garcia Y, Toro V, et al. Depression correlates with increased plasma levels of inflammatory cytokines and a dysregulated oxidant/antioxidant balance in HIV-1-infected subjects undergoing antiretroviral therapy. J Clin Cell Immunol .2014; 5.
99.
Norcini Pala A, Steca P, Bagrodia R, et al. Subtypes of depressive symptoms and inflammatory biomarkers: an exploratory study on a sample of HIV-positive patients. Brain Behav Immun. 2016;56:105–13.PubMedCrossRef
100.
Musinguzi K, Obuku A, Nakasujja N, et al. Association between major depressive disorder and pro-inflammatory cytokines and acute phase proteins among HIV-1 positive patients in Uganda. BMC Immunol. 2018;19:1.PubMedPubMedCentralCrossRef
101.
Poudel-Tandukar K, Bertone-Johnson ER, Palmer PH, Poudel KC. C-reactive protein and depression in persons with human immunodeficiency virus infection: the Positive Living with HIV (POLH) Study. Brain Behav Immun. 2014;42:89–95.PubMedCrossRef
102.•
Lu H, Surkan PJ, Irwin MR, et al. Inflammation and risk of depression in HIV: prospective findings from the Multicenter AIDS Cohort Study. Am J Epidemiol. 2019;188:1994–2003.
103.
Stewart JC, Polanka BM, So-Armah KA, et al. Associations of total, cognitive/affective, and somatic depressive symptoms and antidepressant use with cardiovascular disease-relevant biomarkers in HIV: Veterans Aging Cohort Study. Psychosom Med. 2020;82:461–70.PubMedPubMedCentralCrossRef
104.•
Saloner R, Cherner M, Grelotti DJ, et al. Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease. Brain Behav Immun. 2020;90:353–63.
105.
Ellis R. Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV. Brain Behav Immun. 2020.
106.
Saloner R, Paolillo EW, Heaton RK, et al. Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV. J Neurovirol. 2021;27:160–7.PubMedCrossRef
Metadaten
Titel
Soluble Biomarkers of Cognition and Depression in Adults with HIV Infection in the Combination Therapy Era
verfasst von
Albert M. Anderson
Qing Ma
Scott L. Letendre
Jennifer Iudicello
Publikationsdatum
15.11.2021
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 6/2021
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-021-00581-y

Weitere Artikel der Ausgabe 6/2021

Current HIV/AIDS Reports 6/2021 Zur Ausgabe

Central Nervous System and Cognition (SS Spudich, Section Editor)

Validity of Digital Assessments in Screening for HIV-Related Cognitive Impairment: a Review

Central Nervous System and Cognition (S Spudich, Section Editor)

Central Nervous System Effects of COVID-19 in People with HIV Infection

The Science of Prevention (R Heffron and K Ngure, Section Editors)

Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?

Co-infections and Comorbidity (D Bhattacharya, Section Editor)

HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups

The Science of Prevention (R Heffron and K Ngure, Section Editors)

Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Microbiome Studies in Non-human Primates

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise